MODELING THE COST-EFFECTIVENESS OF THE ALL ORAL, DIRECT-ACTING ANTIVIRAL REGIMEN DACLATASVIR PLUS SOFOSBUVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS (HCV) AND HIV

被引：3
|
作者：
McEwan, P. [1 ]
Ward, T. [1 ]
Webster, S. [1 ]
Kalsekar, A. [2 ]
Brenner, M. [3 ]
Yuan, Y. [2 ]
机构：
[1] Hlth Econ & Outcomes Res Ltd, Monmouth, Wales
[2] Bristol Myers Squibb Pharmaceut Ltd, Princeton, NJ USA
[3] Bristol Myers Squibb Pharmaceut Ltd, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2213
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI32
引用
收藏
页码：A628 / A628
页数：1
相关论文
共 50 条
  • [1] Hepatitis C Direct-Acting Antiviral Agents in HIV/HCV Co-infected Patients
    Valérie Martel-Laferrière
    Douglas T. Dieterich
    Current Treatment Options in Infectious Diseases, 2014, 6 (2) : 132 - 143
  • [2] MODELING THE COST-EFFECTIVENESS OF NOVEL DIRECT ACTING ANTIVIRAL (DAA) TREATMENTS IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS (HCV) AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)
    McEwan, P.
    Ward, T.
    Webster, S.
    Kalsekar, A.
    Brenner, M.
    Yuan, Y.
    VALUE IN HEALTH, 2015, 18 (03) : A239 - A239
  • [3] Response to direct-acting antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients
    Carrasco, Itziar
    Sainz, Talia
    Antoinette Frick, Marie
    Jimenez de Ory, Santiago
    Fortuny, Claudia
    Burgos, Joaquin
    Montero, Marta
    Gavilan, Cesar
    Dolores Falcon, Maria
    Antonio Couceiro, Jose
    Ignacio Bernardino, Jose
    Bisbal, Otilia
    Guerrero, Carmelo
    Teresa Aldamiz-Echevarria, Maria
    Berenguer, Juan
    Luisa Navarro, Maria
    JOURNAL OF VIRAL HEPATITIS, 2020, 27 (09) : 955 - 958
  • [4] Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C
    Hezode, Christophe
    Fourati, Slim
    Chevaliez, Stephane
    Scoazec, Giovanna
    Soulier, Alexandre
    Varaut, Anne
    Francois, Murielle
    Ruiz, Isaac
    Roudot-Thoraval, Francoise
    Mallat, Ariane
    Pawlotsky, Jean-Michel
    CLINICAL INFECTIOUS DISEASES, 2017, 64 (11) : 1615 - 1618
  • [5] Antiviral Treatment for Hepatitis C Virus in HIV/HCV Co-infected Patients
    Ioannou, George N.
    Scott, John D.
    Yang, Yin
    Green, Pamela
    Beste, Lauren A.
    HEPATOLOGY, 2013, 58 : 225A - 225A
  • [6] Treatment of hepatitis C in HIV/HCV co-infected with direct-acting antiviral (DAA) regimens in a single clinic in Tripoli/Libya
    Bousifi, N.
    Ibrahim, K.
    Gumati, W.
    Shwehdi, M.
    Burani, B.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 101 : 296 - 296
  • [7] Estimating the cost-effectiveness of daclatasvir plus sofosbuvir versus sofosbuvir plus ribavirin for patients with genotype 3 hepatitis C virus
    McEwan, Phil
    Webster, Samantha
    Ward, Thomas
    Brenner, Michael
    Kalsekar, Anupama
    Yuan, Yong
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [8] Hepatitis B virus reactivation during direct-acting antiviral therapy in hepatitis B/C co-infected patients on hemodialysis
    Hu, C.
    Wang, J.
    Liu, J.
    Yan, T.
    Yang, Y.
    Chen, T.
    Zhao, Y.
    He, Y.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S294 - S294
  • [9] Direct-acting antiviral treatment of chronic hepatitis C: a single-centre outcome analysis in both HIV/HCV co-infected and HCV mono-infected patients
    Chen, L.
    Lee, T. H.
    Vora, N.
    Sultan, B.
    Reid, D.
    Dakshina, S.
    Gilson, R.
    Waters, L.
    Ghosh, I.
    HIV MEDICINE, 2018, 19 : S149 - S149
  • [10] Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US
    Saab, Sammy
    Parise, Helene
    Virabhak, Suchin
    Wang, Alice
    Marx, Steven E.
    Gonzalez, Yuri Sanchez
    Misurski, Derek
    Johnson, Scott
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (08) : 795 - 805
12345